For instance, NLCs loaded with doxorubicin not only enhanced the tumor‐suppressing effect but also reduced cardiac toxicity in a mouse model of renal cancer.[104] Moreover, NLCs can co‐load immunomodulators (such as IL‐12 and PD‐L1 inhibitors) to synergistically activate anti‐tumor immune responses. The gene discussed is CD274; the disease is neoplasm.